Myeloproliferative syndromes. Current opinions from the European Hematology Association Working Group on Myeloproliferative Disorders.
Brière
J
J
D001241:Aspirin / Q000627:therapeutic use; D001856:Bone Marrow Examination; D002986:Clinical Trials as Topic; D002999:Clone Cells / Q000473:pathology; D003226:Congresses as Topic; D018450:Disease Progression; D005060:Europe / Q000453:epidemiology; D005260:Female; D006133:Growth Substances / Q000502:physiology; D006410:Hematopoiesis; D006412:Hematopoietic Stem Cells / Q000473:pathology; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D015994:Incidence; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009196:Myeloproliferative Disorders / Q000145:classification / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy; D010976:Platelet Count; D011087:Polycythemia Vera / Q000188:drug therapy; D011446:Prospective Studies
D006133:Growth Substances; D001241:Aspirin; D006918:Hydroxyurea